DE3854351D1 - Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern. - Google Patents

Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern.

Info

Publication number
DE3854351D1
DE3854351D1 DE3854351T DE3854351T DE3854351D1 DE 3854351 D1 DE3854351 D1 DE 3854351D1 DE 3854351 T DE3854351 T DE 3854351T DE 3854351 T DE3854351 T DE 3854351T DE 3854351 D1 DE3854351 D1 DE 3854351D1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
site
reducing tissue
inflammed
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3854351T
Other languages
English (en)
Other versions
DE3854351T2 (de
Inventor
Robert F Todd Iii
Paul J Simpson
Benedict R Lucchesi
Stuart F Schlossman
James D Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Michigan
Original Assignee
Dana Farber Cancer Institute Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/061,336 external-priority patent/US4840793A/en
Application filed by Dana Farber Cancer Institute Inc, University of Michigan filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE3854351D1 publication Critical patent/DE3854351D1/de
Publication of DE3854351T2 publication Critical patent/DE3854351T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DE3854351T 1987-06-11 1988-06-03 Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern. Expired - Fee Related DE3854351T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/061,336 US4840793A (en) 1987-06-11 1987-06-11 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US07/165,025 US4935234A (en) 1987-06-11 1988-03-07 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
PCT/US1988/001928 WO1988009672A1 (en) 1987-06-11 1988-06-03 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Publications (2)

Publication Number Publication Date
DE3854351D1 true DE3854351D1 (de) 1995-09-28
DE3854351T2 DE3854351T2 (de) 1996-03-21

Family

ID=26740960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854351T Expired - Fee Related DE3854351T2 (de) 1987-06-11 1988-06-03 Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern.

Country Status (12)

Country Link
US (1) US4935234A (de)
EP (1) EP0371036B1 (de)
JP (1) JPH02503796A (de)
CN (1) CN1034055C (de)
AT (1) ATE126703T1 (de)
AU (1) AU621304B2 (de)
BR (1) BR8807559A (de)
CA (1) CA1317880C (de)
DE (1) DE3854351T2 (de)
DK (1) DK620089A (de)
NO (1) NO894946L (de)
WO (1) WO1988009672A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019648A (en) * 1987-07-06 1991-05-28 Dana-Farber Cancer Institute Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
AU5553290A (en) * 1989-04-28 1990-11-29 Baylor College Of Medicine Dissemination of hiv-1 infected cells
CA2090427A1 (en) * 1990-08-27 1992-02-28 Cetus Oncology Corporation Cd18 peptide medicaments for the treatment of disease
WO1992006697A1 (en) * 1990-10-23 1992-04-30 Repligen Corporation Anti-inflammatory composition
EP0565642A1 (de) * 1991-01-11 1993-10-20 Repligen Corporation Methode zur verhinderung entzündlicher schäden
US5322699A (en) * 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
DE69333447T2 (de) * 1992-05-22 2009-09-10 Montana State University, Bozeman Antikörper mit spezifikäten gegen mehrere adhäsionsmoleküle
WO1994008620A1 (en) * 1992-10-09 1994-04-28 Center For Blood Research, Inc. A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5656441A (en) * 1994-04-19 1997-08-12 Trustees Of Boston University Methods for determining cellular adhesion
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
WO2000048681A2 (en) * 1999-02-17 2000-08-24 Genentech, Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
US6663863B2 (en) 2000-03-17 2003-12-16 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2476896A1 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
JP2008525102A (ja) 2004-12-27 2008-07-17 ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート 電気的な迷走神経刺激による炎症性障害の処置
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2009029614A1 (en) * 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9211409B2 (en) * 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (de) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nervenmanschette mit tasche für einen bleifreien stimulator
WO2011028763A2 (en) * 2009-09-01 2011-03-10 Setpoint Medical Corporation Prescription pad for treatment of inflammatory disorders
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (de) 2009-12-23 2019-09-18 Setpoint Medical Corporation Nervenstimulatoren und systeme zur behandlung von chronischer entzündung
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
EP3668402B1 (de) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagusnervstimulationsvorscreening-test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CA3178409A1 (en) 2020-05-21 2021-11-25 Stavros ZANOS Systems and methods for vagus nerve stimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Also Published As

Publication number Publication date
NO894946L (no) 1990-01-23
DK620089D0 (da) 1989-12-08
CN1033242A (zh) 1989-06-07
CN1034055C (zh) 1997-02-19
WO1988009672A1 (en) 1988-12-15
ATE126703T1 (de) 1995-09-15
DE3854351T2 (de) 1996-03-21
EP0371036A1 (de) 1990-06-06
NO894946D0 (no) 1989-12-08
BR8807559A (pt) 1990-05-22
JPH02503796A (ja) 1990-11-08
DK620089A (da) 1990-02-07
EP0371036A4 (de) 1990-06-27
US4935234A (en) 1990-06-19
AU1946388A (en) 1989-01-04
AU621304B2 (en) 1992-03-12
CA1317880C (en) 1993-05-18
EP0371036B1 (de) 1995-08-23

Similar Documents

Publication Publication Date Title
DE3854351D1 (de) Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE3674308D1 (de) Biozide zusammensetzungund verfahren zur behandlung von wasser.
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
DE3678489D1 (de) Verfahren zur quantitativen bestimmung von protein c und aktivatorpraeparat zur durchfuehrung des verfahrens.
DE68925226D1 (de) Monoklonale Antikörper
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
DE69027220D1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
ATE5002T1 (de) Verfahren und reagenz zur bestimmung von cholesterin.
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
Mebs et al. Snake venom hemorrhagins: neutralization by commercial antivenoms
AT367204B (de) Verfahren und reagenz zur bestimmung des haemoglobingehaltes des blutes
ATE55059T1 (de) Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen.
Mayrhofer et al. IgA‐containing plasma cells in the lamina propria of the gut: failure of a thoracic duct fistula to deplete the numbers in rat small intestine
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
DE58907208D1 (de) Verfahren zur Bestimmung von Antikörpern.
ATE20461T1 (de) Verfahren zur bekaempfung von insekten und cyclopropancarboxylate verwendbar als wirkstoffe dafuer.
EP0070167A3 (de) Hypertension Behandlung
RU97109991A (ru) Способ лечения искусственными минеральными водами
ATE75050T1 (de) Reagenzsatz, seine verwendung und diagnostisches verfahren zur bestimmung von humanen pankreasspezifischen proteinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: RECHTS- UND PATENTANWAELTE REBLE & KLOSE, 68165 MANNHEIM

8339 Ceased/non-payment of the annual fee